ON NEXT BIOTECH today ...... Autism Trial Results a Major Boost...

ON NEXT BIOTECH today ......

Autism Trial Results a Major Boost for NTI’s Proprietary Tech & Children with Autism


Leading medical device company Neurotech International (ASX:NTI) this week reported highly promising results from US clinical trials of its Mente autism device.
Neurotech, through its wholly owned subsidiary AAT Research, has developed the first and only regulated medical device for the management of autism in a home setting.
These US clinical trials tested the efficacy of its proprietary Mente device, a headband developed for children with autism that plays music and sounds to relax the mind via neurofeedback technology.
The results have now been published and NTI surely couldn’t have hoped for a better outcome.
The results, published by leading medical journal Frontiers in Neurology, show that use of the Mente Autism device produced “significant positive changes for children with autism spectrum disorder (ASD) with an improvement towards normalisation”.
Use of the device also led to a reduction in autistic behaviours as well as improved social and communication skills; in addition, changes in participants’ brain activity showed “expected reduction in the frequency bands of interest”.
With the latter, frequency bands of interest is referring to certain brain waves which play a crucial part in autism. People on the autism spectrum have abnormally high Delta and Theta brainwaves, which peak constantly, even when they are awake.
The US clinical trial results also validate Mente Autism as a complementary home-based device for children with ASD.
The results are so positive that NTI is now working hard to complete its preparations for an FDA submission for the Mente Autism device.
Before this, NTI could already cite a long list of testimonials and anecdotal evidence to say that its device had very real potential as a game-changing treatment option for autism.
It should be noted, however, that this is an early stage tech company and success is no guarantee. Investors should seek professional financial advice before making an investment.
In the months leading up to the trial results, the A$16.8 million capped play has been busy securing distribution partners and readying its sales channels in anticipation of the final results.
It has slowly but surely been honing in on its target market across multiple continents, having already signed distribution partners across Germany, Switzerland, Austria, Greece, Australia, India and the Middle East since late 2016.
And it’s a big market we are talking about here.
Autism, or autism spectrum disorder (ASD), is a developmental disorder that affects around 1 in 160people worldwide — or, more than 40 million people across the globe.
Not only are NTI presenting a solution that has been shown to be very effective, it also offers a range of advantages like cost savings and ease of accessibility that position the product in an even more attractive light.
The main two are accessibility — parents and their children can use this product at home, rather than needing to physically attend a clinic, or spend hours at a neurofeedback provider — and cost.
What does anyone want when they’re looking for a product to solve a problem? Convenience and affordability, of course. For those dealing with the particular challenges of raising an autistic child, these benefits become even more crucial.
On that note, let’s check in on our favourite neuro-tech play and learn more about its major news out this week: